CBX is the first identified FOXO3 inhibitor and represents a promising drug for rapid entry into the clinic for NB treatment, as well as other tumors in which inhibition of FOXO3 could be a potential therapeutic strategy. This evidence concerns the gene FOXO3 and neuroblastoma.